In our cohort of BC patients, we noted a worse outcome in the presence of KIR3DL2, thus suggesting that this molecule may be eligible as a target for further treatments in this setting as well as in others, although our data are preliminary for this purpose. This evidence concerns the gene KIR3DL2 and breast cancer.